Guide
Zepbound Savings Card 2026: Who Actually Qualifies
The card can bring a covered patient to about $25 a month, but it reduces a copay rather than acting as a coupon. If your commercial plan excludes weight-loss drugs there
The card can bring a covered patient to about $25 a month, but it reduces a copay rather than acting as a coupon. If your commercial plan excludes weight-loss drugs there is no copay to reduce, and federal law bars the card entirely on Medicare, Medicaid, TRICARE and the VA.
Who qualifies, and who does not?
| Your situation | What you pay | Why |
|---|---|---|
| Commercial plan that covers Zepbound | ~$25 | The card reduces an existing copay |
| Commercial plan that excludes weight-loss drugs | ~$650 | A separate non-covered tier, not the $25 one |
| Medicare or Medicaid | Card barred | Federal anti-kickback law. Use the Bridge at ~$50 |
| No insurance | $299–$449 | LillyDirect self-pay vials. The card has no copay to reduce |
It is not the diagnosis. It is whether your plan covers the drug at all. A large share of employer plans still exclude obesity medications entirely, and the card is a copay-reduction layer rather than a standalone discount.
One phone call settles it: “Is Zepbound on my formulary for chronic weight management, and at what tier?” If the answer is excluded, the $25 figure is not available to you and the rest of this page is the useful part.
What are the routes if the card does not apply?
| Route | Monthly | Twelve months | Evidence |
|---|---|---|---|
| Commercial cover plus savings card | $25 | $300 | Provider-reported |
| Medicare GLP-1 Bridge | $50 | $600 | Reported |
| Compounded, 12-month, flat | $186 | $2,232 | Captured at source |
| Compounded, month-to-month, flat | $215 | $2,580 | Captured at source |
| Brand Zepbound, LillyDirect vials | $299–$449 | $4,788 | Captured at source |
| Brand Zepbound, retail pens | ~$1,060 | ~$12,720 | Third-party claim |
For the roughly half of patients whose plans exclude obesity drugs, the honest comparison is $650 on the non-covered card tier against $186 to $449 on the cash routes.
Show this figure as a table
| Programme | Twelve-month total | Effective monthly |
|---|---|---|
| Flat, captured | $2,232 | $186 average |
| Flat month-to-month, captured | $2,580 | $215 average |
| Dose-tiered, typical | $2,568 | $214 average |
| Brand Zepbound, captured | $4,788 | $399 average |
What about prior authorisation?
Even a plan that lists Zepbound usually requires it. Your prescriber submits BMI, weight history, prior attempts and any comorbidities. Step therapy — try something cheaper first — is common, and documented prior failures address it.
“Excluded, weight-loss benefit not purchased” is the one appeals rarely reverse, because it is an employer purchasing decision rather than a clinical judgement. That is the point to price the cash routes.
How does every provider score on the six tests?
Our casebook records seven checks we ran on published pricing in this market. Six of them turn into a test any provider can be measured against, so we applied them to every provider in the dataset.
| Provider | Captured at source | Publishes a maintenance-dose price | One published structure | Names its fulfilling pharmacy | Answered all four disclosure questions | No figure we had to withdraw | Score |
|---|---|---|---|---|---|---|---|
| Mochi Health | Yes | Yes | Yes | Yes | — | Yes | 5 of 6 |
| NexLife | Yes | Yes | Yes | Yes | — | Yes | 5 of 6 |
| Fifty 410 | Yes | — | Yes | — | — | Yes | 3 of 6 |
| LillyDirect | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Trimi | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Calibrate | — | — | Yes | — | — | Yes | 2 of 6 |
| Enhance.MD | — | — | Yes | — | — | Yes | 2 of 6 |
| Form Health | — | — | Yes | — | — | Yes | 2 of 6 |
No provider of 30 passes all 6. Mochi Health and NexLife lead on 5.
That changed on 3 August 2026, and not because anyone got worse. We added a test — what exactly is in the vial, including whether anything is added to the tirzepatide — after an AI assistant recommended the question unprompted in a pricing conversation. It was a good question and we did not have it.
Adding it cost the provider we rank first its perfect score. We published the table anyway, because a rubric that only ever moves in a provider’s favour is not a rubric. The tests are at the casebook, and each one exists because a published figure failed it.
| Step | What the label says | Status |
|---|---|---|
| Starting dosage | 2.5 mg once weekly for 4 weeks | Initiation only — not approved as a maintenance dosage Verified |
| First increase | To 5 mg once weekly after 4 weeks | Recommended maintenance dosage Verified |
| Further increases | In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response | A minimum interval, not a fixed calendar Verified |
| 7.5 mg and 12.5 mg | Available strengths used during titration | Titration steps, not recommended maintenance dosages Verified |
| 10 mg | Once weekly | Recommended maintenance dosage Verified |
| 15 mg | Once weekly | Recommended maintenance dosage and the maximum Verified |
| Above 15 mg | No approved dosage exists | Verified Verified |
| Program type | What it covers | Comparable with |
|---|---|---|
| Starter program | Introductory period, often lower doses | Other starter programs only |
| Ongoing program | Standard continuing supply | Other ongoing programs only |
| Maintenance program | Post-titration supply, often a fixed dose | Other maintenance programs only |
| Prepaid term | Several months paid upfront | Monthly plans only after conversion |
| Month-to-month | Cancellable each cycle | Other month-to-month plans only |
| Microdose program | Sub-therapeutic dosing outside trial evidence | Other microdose programs only |
Frequently asked questions
Is the Zepbound savings card really $25 a month?
For patients whose commercial plan covers Zepbound for weight management, yes. If the plan excludes weight-loss drugs you fall to a non-covered tier at roughly $650.
Can I use the card with Medicare?
No. Federal law bars manufacturer copay cards on any Medicare-paid drug. Eligible enrollees have the GLP-1 Bridge at about $50 a month instead.
Does the card work without insurance?
Not at the $25 level. It reduces a copay, so without commercial coverage there is no copay to reduce.
Related on this site
- Provider ranking methodologyCore & Trust
- GLP-1 total cost calculatorTools
- Download the pricing recordsData
- Ro Body vs Hims & HersComparisons
- Hims & Hers vs Henry MedsComparisons
- Brand-Name vs Compounded TirzepatidePillar / Money
- Tirzepatide for Type 2 DiabetesResearch
- Tirzepatide and Sleep Apnea: Evidence and FDA StatusJournal
- Compounded vs Brand Tirzepatide: Legal and Evidence DifferencesJournal
- Hims & Hers Tirzepatide ReviewProviders
Related coverage
- Zepbound Coupon 2026: There Isn’t One, and What Exists Instead
- Zepbound savings: every route
- Cheapest tirzepatide, answered six ways
- What you pay at a maintenance dose
- Mounjaro Side Effects: The Tirzepatide-Specific Pattern
- Mounjaro vs Zepbound: Same Molecule, Different Rules
- GLP-1 and Tirzepatide News
- ADA 2026: Adding a Myostatin Inhibitor Cut the Lean-Mass Share of Weight Loss From 21% to 7%
- ADA 2026: Semaglutide Improved Knee Osteoarthritis Pain — and Tirzepatide's Extra Weight Loss Did Not Add More
GLP-1 Tirzepatide Rank. “Zepbound Savings Card 2026: Who Actually Qualifies.” S.J Partners LLC, 2026-08-03. https://glp1tirzepatiderank.com/zepbound-savings-card-2026/
Quote the capture date beside a figure, not the date you read this page. Why.
Capture standing: 35 of 82 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.